An Open‐Label Phase 2a Study to Evaluate the Safety and Tolerability of Perampanel in Cervical Dystonia-Reference-Cited by-同舟云学术

An Open‐Label Phase 2a Study to Evaluate the Safety and Tolerability of Perampanel in Cervical Dystonia

Published:2021-05-13 Issue:5 Volume:8 Page:743-749
ISSN:2330-1619
Container-title:Movement Disorders Clinical Practice
language:en
Short-container-title:Mov Disord Clin Pract

Author:

Fox Susan H.¹²³,Swan Matthew⁴,Jinnah Hyder A.⁵,Freitas Maria E.T.¹²³,Oliveira Lais M.¹²³,Al‐Shorafat Duha¹²³,Fernandez Hubert H.⁶,Kompoliti Katie⁷,Comella Cynthia⁷

Affiliation:

1. The Edmond J Safra Program in Parkinson Disease, Toronto Western Hospital Toronto Ontario Canada

2. Krembil Brain Institute, University Health Network Toronto Ontario Canada

3. Division of Neurology University of Toronto Toronto Ontario Canada

4. Mount Sinai Beth Israel, Icahn School of Medicine at Mount Sinai New York New York USA

5. Department of Human Genetics and Pediatrics Emory University Atlanta Georgia USA

6. Cleveland Clinic Cleveland Ohio USA

7. Rush University Medical Centre Chicago Illinois USA

Publisher

Wiley

Subject

Neurology (clinical),Neurology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/mdc3.13229

Reference33 articles.

1. The focal dystonias: Current views and challenges for future research

2. Dystonia treatment

3. Longitudinal studies of botulinum toxin in cervical dystonia: Why do patients discontinue therapy?

4. An international survey of patients with cervical dystonia

5. The dystonias;Jinnah HA;Continuum (Minneap Minn),2019

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. An Exploratory, Randomized, Double‐Blind Clinical Trial of Dipraglurant for Blepharospasm;Movement Disorders;2024-02-03

2. Perampanel: Medical Alternative for Essential Tremor?;Clinical Neuropharmacology;2023-01-25

3. Advances in targeting neurotransmitter systems in dystonia;International Review of Neurobiology;2023

4. An overview of the pharmacotherapeutics for dystonia: advances over the past decade;Expert Opinion on Pharmacotherapy;2022-11-22

5. ¿Existe evidencia científica para el empleo de perampanel en el dolor neuropático?;Revista de Neurología;2022